Scarica l'app Stockscreener
1.48
5.73%
-0.09
Precedente Chiudi:
$1.57
Aprire:
$1.55
Volume 24 ore:
2.05M
Relative Volume:
0.65
Capitalizzazione di mercato:
$105.24M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-1.9733
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
-11.38%
1M Prestazione:
+27.59%
6M Prestazione:
+412.82%
1 anno Prestazione:
+26.50%
Intervallo 1D:
$1.46
$1.61
Intervallo di 1 settimana:
$1.46
$1.785
Portata 52W:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.48 | 111.64M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
How Ovid Therapeutics Inc. (1OT) stock gains from tech spending2025 Market Trends & Weekly Market Pulse Alerts - Trung tâm Dự báo KTTV quốc gia
Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesShare Buyback & Stepwise Trade Signal Implementation - Trung tâm Dự báo KTTV quốc gia
Why Ovid Therapeutics Inc. stock is popular among millennialsWeekly Trade Analysis & Community Consensus Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Is Ovid Therapeutics Inc. stock a safe buy before earningsTrend Reversal & Free Fast Entry Momentum Trade Alerts - Trung tâm Dự báo KTTV quốc gia
How Ovid Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Breakouts & Growth Focused Stock Reports - Trung tâm Dự báo KTTV quốc gia
Market reaction to Ovid Therapeutics Inc.’s recent news2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Ovid Therapeutics Secures $175.1M in Private Placement - MSN
Will Ovid Therapeutics Inc. (1OT) stock deliver compounding returnsShare Buyback & Low Drawdown Momentum Ideas - newser.com
Ovid Therapeutics Inc (OVID) Technical Analysis - TipRanks
Is Ovid Therapeutics Inc. showing signs of accumulationWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Is a relief rally coming for Ovid Therapeutics Inc. holdersPortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Combining machine learning predictions for Ovid Therapeutics Inc.2025 Volatility Report & Consistent Growth Stock Picks - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - The Globe and Mail
Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener
Ovid Therapeutics Inc (1OT.BE) Stock Price, News, Quote & History - Yahoo
Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com
What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in
Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com
Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business
What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm
Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone - Markets Mojo
Ovid Therapeutics Inc. (OVID) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance
Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating - MarketScreener
What’s next for Ovid Therapeutics Inc. stock priceJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Ovid Therapeutics Sets Market Trends with Successful Trials - Kalkine Media
Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Forecasting Ovid Therapeutics Inc. price range with options data2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Ovid Therapeutics Raises $175 Million Through PIPE Financing - Finimize
Ovid Therapeutics rises on $175 million placing and research update - The Pharma Letter
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Yahoo Finance
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):